The Portland-based Oregon Health & Science University Knight Cancer Institute is partnering with Chicago-based Tempus, a technology company that analyzes molecular and clinical data to develop personalized cancer treatments, to improve care for breast, pancreatic and prostate cancer patients.
Under the agreement, Tempus will provide molecular sequencing, analysis and decision support tools tailored to molecular, clinical and outcome data, as well as patient samples from OHSU.
"We are developing a new, highly personalized approach to clinical trials and working with Tempus will give us access to large datasets that will help inform our therapeutic decisions," said Christopher Corless, MD, PhD, executive director and chief medical officer, Knight Diagnostic Laboratories at the OHSU Knight Cancer Institute.
More articles on data analytics & precision medicine:
4 common roadblocks to adopting predictive analytics in healthcare organizations
Mount Sinai spinout Sema4 taps Dr. Jamie Coffin for president, COO
Using predictive analytics to boost operational efficiency: 4 experts weigh in